Prostate Cancer
What's New
Last Posted: Jun 27, 2024
- Screening guidelines for people at increased risk for prostate cancer.
Justin Lorentz et al. Can Urol Assoc J 2024 - Development of a Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage.
Michael S Leapman et al. JAMA Netw Open 2024 7(6) e2417274 - The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
Elizabeth K Bancroft et al. BJU Int 2024 - Development and validation of a machine learning model for bone metastasis in prostate cancer: Based on inflammatory and nutritional indicators.
Tongtong Jin et al. Urology 2024 - Utilization of A Third-Party Partnership in Tele-genetic Risk Assessment Program in Genitourinary Oncology.
Lin Lin et al. Urology 2024 - Catalyzing Precision Medicine: Artificial Intelligence Advancements in Prostate Cancer Diagnosis and Management.
Ali Talyshinskii et al. Cancers (Basel) 2024 16(10) - The acceptability and clinical impact of using polygenic scores for risk-estimation of common cancers in primary care: a systematic review
- Prospective Study of Homologous Recombination Repair Gene Mutation Prevalence in Patients With Advanced Prostate Cancer From Latin America: Challenges and Future Approaches.
Ray Manneh et al. JCO Precis Oncol 2024 8e2300628 - Men with metastatic prostate cancer carrying a pathogenic germline variant in breast cancer genes: disclosure of genetic test results to relatives.
Michiel Vlaming et al. Fam Cancer 2024 - Outcomes of a universal germline screening program in a community urology practice.
Neil Mendhiratta et al. Clin Genet 2024 - Trial of Electronic Medical Record Integrated Next-Generation Sequencing Ordering in Veterans Affairs Cancer Care.
James H Stoeckle et al. JCO Precis Oncol 2024 8e2300463 - Real-world utilization, patient characteristics, and treatment patterns among men with localized prostate cancer tested with the 17-gene genomic prostate score® (GPS) assay.
Amy M Nguyen et al. Prostate 2024 - Predictive value of magnetic resonance imaging diffusion parameters using artificial intelligence in low-and intermediate-risk prostate cancer patients treated with stereotactic ablative radiotherapy: A pilot study.
A Kedves et al. Radiography (Lond) 2024 30(3) 986-994 - Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer
- Clinical features of prostate cancer by polygenic risk score.
Christina Spears et al. Fam Cancer 2024 - Impact of Family History and Germline Genetic Risk Single Nucleotide Polymorphisms on Long-Term Outcomes of Favorable-Risk Prostate Cancer.
Florian Rumpf et al. J Urol 2024 101097JU0000000000003927 - Somatic Tumor Testing in Prostate Cancer: Experience of a Tertiary-Care Center Including Pathologist-Driven Reflex Testing of Localized Tumors at Diagnosis.
Susan Prendeville et al. Mod Pathol 2024 100489 - Explainable and visualizable machine learning models to predict biochemical recurrence of prostate cancer.
Wenhao Lu et al. Clin Transl Oncol 2024 - Men's sociotechnical imaginaries of artificial intelligence for prostate cancer diagnostics - A focus group study.
Emilie Hybertsen Lysø et al. Soc Sci Med 2024 347116771 - Tissue-Based Genomic Testing in Prostate Cancer: 10-Year Analysis of National Trends on the Use of Prolaris, Decipher, ProMark, and Oncotype DX.
Eugenio Bologna et al. Clin Pract 2024 14(2) 508-520 - Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre.
Xin Wang et al. Clin Genitourin Cancer 2024 102052 - TARGET: A Randomized, Noninferiority Trial of a Pretest, Patient-Driven Genetic Education Webtool Versus Genetic Counseling for Prostate Cancer Germline Testing.
Stacy Loeb et al. JCO Precis Oncol 2024 8e2300552 - The cost-effectiveness of germline BRCA testing-guided olaparib treatment in metastatic castration resistant prostate cancer.
Srinivas Teppala et al. Int J Technol Assess Health Care 2024 40(1) e14 - Development and Validation of a Deep Learning Model to Reduce the Interference of Rectal Artifacts in MRI-based Prostate Cancer Diagnosis.
Lei Hu et al. Radiol Artif Intell 2024 e230362 - Machine learning prediction of Gleason grade group upgrade between in-bore biopsy and radical prostatectomy pathology.
Kaan Ozbozduman et al. Sci Rep 2024 14(1) 5849 - Prediction of clinically significant prostate cancer using radiomics models in real-world clinical practice: a retrospective multicenter study.
Jie Bao et al. Insights Imaging 2024 15(1) 68 - Highly accurate and effective deep neural networks in pathological diagnosis of prostate cancer.
Chengwei Zhang et al. World J Urol 2024 42(1) 93 - Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
Arnab Basu et al. J Natl Cancer Inst 2024 2 - Germline mutations of 4567 patients with hereditary breast-ovarian cancer spectrum in Thailand.
Chalermkiat Kansuttiviwat et al. NPJ Genom Med 2024 9(1) 9 - Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
Adalgisa Guerra et al. Cancer Imaging 2024 24(1) 24 - Real-world data on the comprehensive genetic profiling test for Japanese patients with metastatic castration-resistant prostate cancer.
Dai Koguchi et al. Jpn J Clin Oncol 2024 - Forget lung, breast or prostate cancer: why tumour naming needs to change The conventional way of classifying metastatic cancers according to their organ of origin is denying people access to drugs that could help them.
F Andre et al, Nature, January 31, 2024 - Germline Mutations and Ancestry in Prostate Cancer.
Eudoxie Bataba et al. Curr Oncol Rep 2024 - Concurrent Tissue and Circulating Tumor DNA Molecular Profiling to Detect Guideline-Based Targeted Mutations in a Multicancer Cohort.
Wade T Iams et al. JAMA Netw Open 2024 7(1) e2351700 - Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
Kyung Min Lee et al. J Natl Cancer Inst 2024 1 - Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.
Michael S Leapman et al. BJUI Compass 2024 5(1) 142-149 - Air quality and cancer risk in the All of Us Research Program.
Andrew Craver et al. Cancer Causes Control 2023 - Pilot Trial of Streamlined Genetic Education and Traceback Genetic Testing in Prostate Cancer Survivors.
Marc D Schwartz et al. J Natl Compr Canc Netw 2023 21(12) 1261-1268.e14 - A convolutional neural network-based system for fully automatic segmentation of whole-body [Ga]Ga-PSMA PET images in prostate cancer.
Esmail Jafari et al. Eur J Nucl Med Mol Imaging 2023 - The ENGAGE study: evaluation of a conversational virtual agent that provides tailored pre-test genetic education to cancer patients.
Kala Visvanathan et al. J Cancer Surviv 2023 - An Australian mainstream genetic testing program: Clinicians views about current and future practices.
Alison Luk Young et al. Asia Pac J Clin Oncol 2023 - Comparing Active Surveillance and Watchful Waiting With Radical Treatment Using Machine Learning Models Among Patients With Prostate Cancer.
Siqi Hu et al. JCO Clin Cancer Inform 2023 7e2300083 - Danish Prostate Cancer Consortium Study 1 (DPCC-1) protocol: Multicentre prospective validation of the urine-based three-microRNA biomarker model uCaP.
Jacob Fredsøe et al. BMJ Open 2023 13(11) e077020 - NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024.
Mary B Daly et al. J Natl Compr Canc Netw 2023 21(10) 1000-1010 - Comprehensive genomic profiling testing in Japanese castration-resistant prostate cancer patients: results of a single-center retrospective cohort study.
Takafumi Fukushima et al. Jpn J Clin Oncol 2023 - Development of machine learning prognostic models for overall survival of prostate cancer patients with lymph node-positive.
Zi-He Peng et al. Sci Rep 2023 13(1) 18424 - Male awareness of prostate cancer risk remains poor in relatives of women with germline variants in DNA-repair genes.
Vittorio Fasulo et al. BJUI Compass 2023 4(6) 738-745 - Prediction of clinically significant prostate cancer through urine metabolomic signatures: A large-scale validated study.
Hsiang-Po Huang et al. J Transl Med 2023 21(1) 714 - Machine learning-based prediction model and visual interpretation for prostate cancer.
Gang Chen et al. BMC Urol 2023 23(1) 164 - Performance of deep learning models for response evaluation on whole-body bone scans in prostate cancer.
Sangwon Han et al. Ann Nucl Med 2023 - An Actionable Expert-System Algorithm to Support Nurse-Led Cancer Survivorship Care: Algorithm Development Study.
Kaylen J Pfisterer et al. JMIR Cancer 2023 9e44332 - Emerging cancer risks in BRCA2 pathogenic germline variant carriers.
Patrick R Benusiglio et al. Eur J Hum Genet 2023 9 - Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.
Burcu F Darst et al. JAMA Oncol 2023 9 - Biomarker-Directed Therapy in Black and White Men With Metastatic Castration-Resistant Prostate Cancer.
Clara Hwang et al. JAMA Netw Open 2023 9 (9) e2334208 - Evaluation of a Deep Learning-based Algorithm for Post-Radiotherapy Prostate Cancer Local Recurrence Detection Using Biparametric MRI.
Enis C Yilmaz et al. Eur J Radiol 2023 168111095 - Efficacy of National Comprehensive Cancer Network Guidelines in Identifying Pathogenic Germline Variants Among Unselected Patients with Prostate Cancer: The PROCLAIM Trial.
Neal Shore et al. Eur Urol Oncol 2023 - Don't Fear the Artificial Intelligence: A Systematic Review of Machine Learning for Prostate Cancer Detection in Pathology.
Aaryn Frewing et al. Arch Pathol Lab Med 2023 - An international multi-institutional validation study of the algorithm for prostate cancer detection and Gleason grading
Y Tolkach et al, NPJ Precision Oncology, August 15, 2023 - BRCA-deficient metastatic prostate cancer has an adverse prognosis and distinct genomic phenotype
H Fettle et al, ebiomedicine, August 5, 2023 - Artificial intelligence for the diagnosis of clinically significant prostate cancer based on multimodal data: a multicenter study.
Huiyong Zhang et al. BMC Med 2023 21(1) 270 - Enhancing Triage Efficiency and Accuracy in Emergency Rooms for Patients with Metastatic Prostate Cancer: A Retrospective Analysis of Artificial Intelligence-Assisted Triage Using ChatGPT 4.0.
Georges Gebrael et al. Cancers (Basel) 2023 15(14) - The predictive value of machine learning and nomograms for lymph node metastasis of prostate cancer: a systematic review and meta-analysis.
Hao Wang et al. Prostate Cancer Prostatic Dis 2023 - Genetic testing practices among specialist physicians who treat prostate cancer: A Canadian cross-sectional survey.
Steven M Yip et al. Can Urol Assoc J 2023 - Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.
Charlie Massie et al. BJU Int 2023 - Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
Olivier Cussenot et al. BJU Int 2023 - Mutations in epigenetic regulator KMT2C detected by liquid biopsy are associated with worse survival in prostate cancer patients.
Sha Zhu et al. Oncol Res 2023 31(4) 605-614 - Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.
Giorgio Gandaglia et al. Eur Urol 2023 - Meeting the need for germline testing
Lancet Oncology editorial, July 2023 - Germline DNA Repair Genes Pathogenic Variants Among Mexican Patients With Prostate Cancer.
Yanin Chávarri-Guerra et al. Clin Genitourin Cancer 2023 - Temporal and Racial Trends in Prostate Specific Antigen Screening for US Men With Family History of Prostate Cancer.
Deepansh Dalela et al. Urol Pract 2023 101097UPJ0000000000000419
More
About Cancer PHGKB
Cancer PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to cancer...more
Content Summary
Common Type
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by Public Health Genomics Branch to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2024
- Content source: